Horimed raises over 100 million RMB to build integrated intravascular imaging, cardiac ultrasound, and laser ablation platform

Recently, Horimed Technology announced the completion of a financing round exceeding 100 million RMB. This round was led by CICC Capital and Wuxi Capital Group, with additional investment from existing shareholder Chengdu Sci-Tech Venture Capital. Star Bridge Capital served as the long-term exclusive financial advisor. This is a significant financing round completed by Horimed in early 2026, which will help Horimed further accelerate the R&D, manufacturing, and commercialization of its vascular interventional intra-imaging and therapeutic products.

Horimed has established a strong presence in the field of vascular intervention, committed to building a technology and product system covering the entire process of precision diagnosis and treatment through continuous innovation. Centered around its two core pillars — intravascular ultrasound (IVUS) and optical coherence tomography (OCT) — Horimed has, after years of dedicated effort, built a full-chain framework spanning core components, complete equipment, and system solutions.

Leveraging its capability of simultaneously mastering both IVUS and OCT core technologies, Horimed continues to promote the coordinated development of its dual-technology pathway, strengthening its comprehensive competitiveness in the field of precision vascular interventional diagnosis and treatment. In addition, Horimed's self-developed 2D ICE and 4D ICE, as well as its all-in-one cardiac ultrasound system, have been steadily progressing. The company's major laser product line is also being continuously improved, further consolidating its platform-based strategy.

With the deepening of precision medicine and the growing demand for standardized surgical procedures, the need for real-time, accurate intraoperative imaging navigation in vascular interventions is increasing rapidly. China has a large population of patients with cardiovascular diseases, and the number of coronary intervention procedures performed annually continues to grow. However, the penetration rate of intravascular imaging technology in China still lags behind that of developed countries, a gap that represents significant market potential and growth opportunities.

As clinical guidelines increasingly recommend the use of intravascular imaging technology and as the technology becomes more widely adopted, China's domestic intravascular imaging market is poised to enter a period of rapid growth. Leveraging its comprehensive product portfolio and its accumulated expertise in AI-powered medical technology, Horimed has built an integrated solution combining image acquisition, intelligent analysis, and surgical guidance, positioning itself to fully capitalize on the upcoming growth of the AI precision medicine market.

Horimed is undergoing a strategic transformation from a "cardiovascular expert" to a "pan-vascular platform." Behind this shift is Horimed's deep insight into the vascular disease diagnosis and treatment market and its forward-looking strategic planning.

Based on in-depth market analysis and technical assessment, Horimed has expanded its portfolio to include cerebrovascular OCT, carotid artery OCT, peripheral vascular IVUS, and an OCT+IVUS+NIRS multimodal imaging system. On the cardiac ultrasound front, the 2D ICE system has entered the registration phase; the 4D ICE system (an industry-leading ASIC+PZT electronic matrix mode) is expected to enter the registration phase by the end of 2026; and the all-in-one ICE+TTE+TEE cardiac ultrasound system is also expected to enter the registration phase in 2026.

It is worth noting that 4D ultrasound systems offer advantages over 2D ultrasound products in areas such as three-dimensional spatial imaging, dynamic real-time display, precise quantitative analysis, and surgical navigation. Regarding the laser ablation system, the all-solid-state ultraviolet tunable laser system is currently undergoing product development, with multiple sets of phantom experiments and in vivo animal studies already completed. The experimental results have demonstrated that this technical approach has clear advantages.

This ecosystem expansion is made possible by Horimed's solid underlying technology foundation and the team's continuous self-iteration capabilities. The cross-indication expansion not only reduces technology R&D risks but also opens up broad development space for Horimed to further expand its business footprint.